News

News and features

Sign up for email alerts of latest news, events, new funding opportunities and more.

Stem cell-derived liver models allow scientists to test treatments for drug overdoses

1 Nov 2017

Scientists at the MRC Centre for Regenerative Medicine at the University of Edinburgh have developed a new technique using stem cells to generate a liver ‘model’. Using this model, the team showed in 2016 that a novel microRNA – a tiny molecule that can switch genes on or off -- could reduce drug-induced liver toxicity, which could lead to developing new treatments for paracetamol overdoses. 

Gene therapy successfully treats 'Bubble Boy disease' in children

1 Nov 2017

MRC-funded scientists at the UCL Institute of Child Health have developed a successful treatment for children with ‘Bubble boy disease’, a rare immune disorder. In 2015, this work led to the launch of Orchard Therapeutics, a spin-out company which aims to further develop gene therapy to benefit patients with serious and life-threatening diseases.

MRC research influences NHS Diabetes Prevention Programme

1 Nov 2017

The NHS Diabetes Prevention Programme was launched in 2016, and will eventually cover 26 million people. Two researchers funded through the MRC-led National Prevention Research Initiative have been influential in contributing to this important programme, demonstrating a compelling example of prevention research being translated into healthcare to improve human lives.

MRC project crowned winner of Newton Prize in India

1 Nov 2017

An MRC Newton-funded project has been awarded the Newton Prize worth £200,000 at an event in New Delhi today, for testing the introduction of a new vital sign device into routine maternity care in hospitals in India and Africa.

Daily pill to prevent HIV infection: the PROUD Study

1 Nov 2017

The ground-breaking results from the PROUD study, published in 2016, indicate that a treatment known as PrEP is highly protective for a high-risk group of people, reducing the risk of infection by 86 per cent. This protection is the highest reported from a randomised controlled trial of PrEP to date